Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori

Yuan,Yuping; Wu,Qinyi; Cheng,Guoxiang; Liu,Xuefang; Liu,Siguo; Luo,Juan; Zhang,Aimin; Bian,Li; Chen,Jianquan; Lv,Jiajun; Dong,Xiangqian; Yang,Gang; Zhu,Yunzhen; Ma,Lanqing

doi:10.3892/ijmm.2015.2251

Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori

Authors:
- Yuping Yuan
- Qinyi Wu
- Guoxiang Cheng
- Xuefang Liu
- Siguo Liu
- Juan Luo
- Aimin Zhang
- Li Bian
- Jianquan Chen
- Jiajun Lv
- Xiangqian Dong
- Gang Yang
- Yunzhen Zhu
- Lanqing Ma
View Affiliations

Affiliations: Yunnan Institute of Digestive Disease, Department of Digestive Diseases, The First Affiliated Hospital, Kunming Medical University, Kunming, Yunnan, P.R. China, Laboratory for Conservation and Utilization of Bio‑Resources, Yunnan University, Kunming, Yunnan, P.R. China, Shanghai Jielong Bioengineering Co., Ltd., Shanghai, P.R. China, Department of Pathology, The First Affiliated Hospital, Kunming Medical University, Kunming, Yunnan, P.R. China
Published online on: June 17, 2015 https://doi.org/10.3892/ijmm.2015.2251
Pages: 363-368
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Helicobacter pylori (H. pylori) is a life-threatening pathogen which causes chronic gastritis, gastric ulcers and even stomach cancer. Treatment normally involves bacterial eradication; however, this type of treatment only has a rate of effectiveness of <80%. Thus, it is a matter of some urgency to develop new therapeutic strategies. Lactoferrin, a member of the transferrin family of iron‑binding proteins, has been proven to be effective in removing a vast range of pathogens, including H. pylori. In the present study, we examined the effectiveness of recombinant human lactoferrin (rhLf) isolated from transgenic goats as a treatment for H. pylori in vitro and in vivo. For the in vivo experiments, BALB/c mice received an intragastric administration of 0.1 ml of a suspension of H. pylori. The mice were then divided into 4 groups: group A, treated with saline; group B, treated with 1.5 g of rhLF; group C, treated with the standard triple therapy regimen; and group D, treated with the standard triple therapy regimen plus.5 g of rhLF. Following sacrifice, the stomach tissues of the mice were histologically examined for the presence of bacteria. For the in vitro experiments, the bacteria were cultured in BHI broth and RT-qPCR and western blot analysis were carried out to determine the mRNA and protein levels of virulence factors (CagA and VacA) in the cultures. Our results revealed that rhLf not only inhibited the growth of H. pylori, but also suppressed the expression of two major virulence factors. Moreover, rhLf markedly increased bacterial eradication and effectively reduced the inflammatory response when combined with the standard triple therapy regimen. These results provide evidence supporting the use of rhLF as an adjuvant to traditional therapeutic strategies in the treatment of H. pylori.

View Figures

View References

1	Bytzer P, Dahlerup JF, Eriksen JR, Jarbøl DE, Rosenstock S and Wildt S; Danish Society for Gastroenterology: Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull. 58:C42712011.PubMed/NCBI
2	Olokoba AB, Obateru OA and Bojuwoye MO: Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 54:1–4. 2013. View Article : Google Scholar : PubMed/NCBI
3	Murphy G, Michel A, Taylor PR, Albanes D, Weinstein SJ, Virtamo J, Parisi D, Snyder K, Butt J, McGlynn KA, et al: Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study. Hepatology. 60:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
4	Leung WK and Graham DY: Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol. 5:133–138. 2002. View Article : Google Scholar : PubMed/NCBI
5	Gisbert JP and Pajares JM: Review article: Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 16:1047–1057. 2002. View Article : Google Scholar : PubMed/NCBI
6	Dresner D, Coyle W, Nemec R, Peterson R, Duntemann T and Lawson JM: Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. South Med J. 89:775–778. 1996. View Article : Google Scholar : PubMed/NCBI
7	Sanaka M, Kuyama Y, Yamanaka M and Iwasaki M: Decrease in serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin. Am J Gastroenterol. 94:1983–1984. 1999. View Article : Google Scholar : PubMed/NCBI
8	Kusters JG, van Vliet AH and Kuipers EJ: Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 19:449–490. 2006. View Article : Google Scholar : PubMed/NCBI
9	Vorland LH: Lactoferrin: a multifunctional glycoprotein. APMIS. 107:971–981. 1999. View Article : Google Scholar : PubMed/NCBI
10	Farnaud S and Evans RW: Lactoferrin: a multifunctional protein with antimicrobial properties. Mol Immunol. 40:395–405. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ikeda M, Nozaki A, Sugiyama K, Tanaka T, Naganuma A, Tanaka K, Sekihara H, Shimotohno K, Saito M and Kato N: Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 66:51–63. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ellison RT III, Giehl TJ and LaForce FM: Damage of the outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 56:2774–2781. 1988.PubMed/NCBI
13	Drago-Serrano ME, de la Garza-Amaya M, Luna JS and Campos-Rodriguez R: Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol. 12:1–9. 2012. View Article : Google Scholar
14	Di Mario F, Aragona G, Bò ND, Ingegnoli A, Cavestro GM, Moussa AM, Iori V, Leandro G, Pilotto A and Franzè A: Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J Clin Gastroenterol. 36:396–398. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sachdeva A and Nagpal J: Meta-analysis: efficacy of bovine lacto-ferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 29:720–730. 2009. View Article : Google Scholar : PubMed/NCBI
16	de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, et al: Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 102:951–956. 2007. View Article : Google Scholar : PubMed/NCBI
17	Guttner Y, Windsor HM, Viiala CH and Marshall BJ: Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther. 17:125–129. 2003. View Article : Google Scholar
18	Miehlke S, Reddy R, Osato MS, Ward PP, Conneely OM and Graham DY: Direct activity of recombinant human lactoferrin against Helicobacter pylori. J Clin Microbiol. 34:2593–2594. 1996.PubMed/NCBI
19	Peek RM Jr and Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2:28–37. 2002. View Article : Google Scholar : PubMed/NCBI
20	Vergara M, Vallve M, Gisbert JP and Calvet X: Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 18:647–654. 2003. View Article : Google Scholar : PubMed/NCBI
21	Altintas E, Sezgin O, Ulu O, Aydin O and Camdeviren H: Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 10:1656–1658. 2004.PubMed/NCBI
22	Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG and Lichtenberger LM: Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci. 43:2750–2756. 1998. View Article : Google Scholar
23	Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R and Covacci A: cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA. 93:14648–14653. 1996. View Article : Google Scholar : PubMed/NCBI
24	Christie PJ and Vogel JP: Bacterial type IV secretion: conjugation systems adapted to deliver effector molecules to host cells. Trends Microbiol. 8:354–360. 2000. View Article : Google Scholar : PubMed/NCBI
25	Fischer W, Puls J, Buhrdorf R, Gebert B, Odenbreit S and Haas R: Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol. 42:1337–1348. 2001. View Article : Google Scholar
26	Papini E, Satin B, Norais N, de Bernard M, Telford JL, Rappuoli R and Montecucco C: Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin. J Clin Invest. 102:813–820. 1998. View Article : Google Scholar : PubMed/NCBI
27	Cover TL and Blanke SR: Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 3:320–332. 2005. View Article : Google Scholar : PubMed/NCBI